CHITOSE will participate in the BIO International Convention 2026, to be held from June 22nd to 25th at the San Diego Convention Center. 

As the global biotech community gathers in San Diego, we are eager to meet with industry leaders and innovators to discuss how our platform using highly productive cell lines can drive the social implementation of next-generation biologics.

Schedule a Meeting with Us
We invite you to discuss your projects in biologics and gene therapy leveraging our high-yield cell platforms. Whether you are looking to optimize yields or shorten manufacturing timelines, our biopharmaceutical manufacturing team is ready to explore how we can support you with our technologies:

▪️ CHO-MK cell line: the world’s most productive CHO cell line that can produce 10g/L of antibodies in only 5 culture days. Developed for high-titer, robust therapeutic protein expression.
▪️ Human Amniotic epithelial cell line for gene and cell Therapy (HAT): a novel host cell line for gene therapy, demonstrating high AAV vector yield, and enhanced product quality.

To connect with us in San Diego, please reach out via the BIO One-on-One Partnering™ system or directly at the email address below:

biologics.contact◎chitose-bio.com
*replace ◎ with @

Event Overview
Event Name: BIO International Convention 2026
Date and Time: Monday, June 22nd – Thursday, June 25th, 2026
Venue: San Diego Convention Center (San Diego, CA, USA)

About CHITOSE’s Cell Line Development Service
https://biologics.chitose-bio.com/
Through over 10 years of research, CHITOSE has developed the highly productive CHO-MK host cell line and designed the original Chitose Super CHO expression system (CS CHO). With the combination of these innovations, we have established an extremely robust and flexible system to address the needs for a faster and more cost-effective cell line-based protein expression platform.

Related Information
[Press Release] The University of Tokyo and Chitose Laboratory Drive New Development in Digital Design for Manufacturing Process of Antibody Drugs
[Press Release] CHITOSE and FUJIFILM Biosciences Form Strategic Alliance to Drive Global Innovation and Biopharmaceutical Manufacturing
[News] Paper on Novel CHO-MK Cell Line Receives 2025 Excellent Paper Award from the Society of Biotechnology, Japan
[Press Release] High-Performance Novel HAT Cell Line for Gene Therapy, Published in Molecular Therapy Methods & Clinical Development, and Ready for Commercial Use